The DOCK11 Knockout MES-OV Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal cell population derived from the human ovarian epithelial carcinoma cell line MES-OV. This polyclonal knockout model provides a heterogeneous pool of cells carrying diverse disruptive mutations at the DOCK11 locus, enabling the study of gene function without clonal artifacts. The use of CRISPR/Cas9 technology allows efficient disruption of the target gene, generating a functional knockout suitable for investigating the role of DOCK11 in cellular processes. As a polyclonal population, this product maintains the genetic diversity of the parental cell line while exhibiting targeted loss of DOCK11 expression.
The host cell line MES-OV is an established epithelial ovarian cancer cell model originally derived from a patient with ovarian carcinoma. This cell line recapitulates key features of ovarian epithelial carcinoma, making it a valuable tool for studying ovarian cancer biology. MES-OV cells exhibit characteristic epithelial morphology and tumorigenic properties, and they are widely used in preclinical research to explore molecular mechanisms driving ovarian cancer progression, including cell migration, invasion, and metastasis. The ovarian cancer context is particularly relevant given the known roles of Rho GTPase signaling in tumor cell dissemination.
DOCK11 encodes a guanine nucleotide exchange factor (GEF) that specifically activates the small GTPase CDC42 by catalyzing the exchange of GDP for GTP. Activated CDC42 then triggers downstream effectors such as PAK1 and WASP, which orchestrate actin polymerization and cytoskeletal remodeling. This signaling cascade is initiated by upstream signals from receptor tyrosine kinases, PI3K, and the lipid messenger PIP3. DOCK11 also interacts with ELMO proteins, which may modulate its activity. Through this pathway, DOCK11 regulates actin dynamics, cell shape, and directional cell migration, playing a critical role in normal cellular functions and pathological processes such as cancer invasion.
In the context of ovarian cancer, DOCK11-mediated CDC42 signaling contributes to the invasive and migratory capacity of tumor cells. Disruption of DOCK11 in MES-OV polyclonal cells is expected to impair CDC42 activation and downstream actin reorganization, providing a powerful model to dissect the molecular mechanisms of ovarian cancer cell motility. This knockout system also allows exploration of DOCK11??s involvement in related diseases such as combined immunodeficiency and inflammatory conditions, where Rho GTPase signaling is implicated. By comparing these knockout cells with wild-type controls, researchers can delineate DOCK11-dependent phenotypes and identify novel therapeutic targets.
Researchers can employ this polyclonal knockout model in a wide range of functional assays to investigate DOCK11 biology. Typical applications include transwell migration assays, Matrigel invasion assays, and phalloidin-based actin staining to assess cytoskeletal changes. Biochemical analyses such as active CDC42 pull-downs, western blotting, and immunofluorescence enable quantification of signaling pathway alterations. These cells are valuable for drug discovery efforts targeting Rho GTPase signaling and for functional characterization of DOCK11 in ovarian cancer and beyond. For additional technical details, please contact Ascent Research.
